Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On March 25, 2026, our Board authorized the repurchase, from time to time, with no expiration date, of up to $200.0 million aggregate purchase price (excluding any fees, commissions, or other expenses of such purchases) of Cimpress' issued and outstanding ordinary shares on the open market, through privately negotiated transactions, or in one or more self-tender offers. This authorization replaced the remaining unused portion of the $200.0 million share repurchase authorization previously approved by our Board on May 29, 2024, which was terminated immediately prior to the effectiveness of the new authorization. The Board’s authorization does not necessarily mean that we will repurchase the full dollar amount authorized. Share repurchases remain subject to Cimpress’ net leverage and capital allocation priorities and may be suspended or discontinued at any time.
The following table outlines the repurchase of our ordinary shares during the three months ended March 31, 2026, under the program described above:
Total Number of Shares Purchased Average Price Paid Per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet be Purchased Under the Program
(in millions)
January 1, 2026 through January 31, 2026 168,365 $ 76.13 168,365 $ 74.3
February 1, 2026 through February 28, 2026 119,744 75.77 119,744 65.2
March 1, 2026 through March 31, 2026 — — — 200.0
Total 288,109 $ 75.98 288,109 $ 200.0
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.